Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 17, 2024Biomedicine & PharmacotherapyOpen Access

Combined dapagliflozin and roxadustat effectively protected heart and kidney against cardiorenal syndrome-induced damage in rodent through activation of cell stress-Nfr2/ARE signalings and stabilizing HIF-1α

View Full Paper
Ask AI
Bookmark
Share

Key result

Combined dapagliflozin and roxadustat therapy synergistically protected heart and kidney functions against cardiorenal syndrome-induced damage in rats compared to singular therapy (p<0.0001).

Why the study?

It was unknown whether combined dapagliflozin and roxadustat therapy was superior to singular therapy in protecting heart and kidney functions in cardiorenal syndrome.

Does combined dapagliflozin and roxadustat improve heart and kidney functions in a rodent model of cardiorenal syndrome?

Population

Adult-male SD rats

Comparison

CRS+ROX+DAPA vs sham control, untreated CRS, CRS+ROX, and CRS+DAPA

Design

Animal and in vitro controlled laboratory study

Follow-up

Day 60 after rodent CRS induction

Authors

PSPei‐Hsun SungYYYa YueYCYi-Ling Chen

Discussion

Loading...

Member takes

Overview

Animal data suggest DAPA-ROX synergy in rat CRS; leaves open translation to human cardiorenal syndrome.

Structured PICO

Does combined dapagliflozin and roxadustat improve heart and kidney functions in a rodent model of cardiorenal syndrome?

P
Population
Adult-male SD rats with induced cardiorenal syndrome treated with dapagliflozin, roxadustat, or both for 60 days.
I
Intervention
Combined dapagliflozin and roxadustat therapy
C
Comparator
Sham-operated control, untreated CRS, CRS + roxadustat alone, and CRS + dapagliflozin alone
O
Outcome
Heart and kidney functions (BUN/creatinine, urine protein to creatinine ratio, left-ventricular-ejection-fraction) and protein expression levels of signaling factors at Day 60surrogate

Main Result

p-value: p=<0.0001

Combined dapagliflozin and roxadustat therapy synergistically protects heart and kidney functions in a rodent model of cardiorenal syndrome.

Cite This Study

Sung et al. (2024) studied Cardiorenal syndrome. Combined dapagliflozin and roxadustat vs. Singular therapy (dapagliflozin or roxadustat) and sham control was evaluated on Heart and kidney functions (BUN/creatinine, urine protein to creatinine ratio, left ventricular ejection fraction) (p=<0.0001). Combined dapagliflozin and roxadustat therapy synergistically protected heart and kidney functions against cardiorenal syndrome-induced damage in rats compared to singular therapy (p<0.0001).

synapsesocial.com/papers/6a78478c98f24dbf64bdc19ehttps://doi.org/10.1016/j.biopha.2024.117567
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through <scp>AMPK</scp> Activation and Angiotensin <scp>II</scp> Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome2026 · 2 citations
  2. 2SGLT2 inhibitor downregulated oxidative stress via activating AMPK pathway for cardiorenal (CR) protection in CR syndrome rodent fed with high protein diet2024 · 18 citations
  3. 3The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats2020 · 27 citations
  4. 4Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity2024 · 34 citations
  5. 5Roxadustat improves diabetic myocardial injury by upregulating HIF-1α/UCP2 against oxidative stress2025 · 20 citations